Bottom line
CagriSema — a once-weekly combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist) — validated the multi-pathway approach with roughly 20% or greater average weight loss versus placebo in REDEFINE 1, along with clinically meaningful blood-pressure reductions. But in REDEFINE 4, the open-label head-to-head against tirzepatide (Zepbound), CagriSema did not meet its primary endpoint of non-inferiority: 23.0% average weight loss versus 25.5% with tirzepatide at 84 weeks. CagriSema is not yet FDA-approved; the application is under review with a decision expected late 2026.
Current regulatory status
CagriSema is investigational in the United States. Novo Nordisk filed its New Drug Application on December 18, 2025, based on the placebo-controlled REDEFINE 1 trial, and the FDA is expected to issue a decision in late 2026. It is not available outside clinical trials.
How CagriSema is different
Semaglutide is a GLP-1 receptor agonist. Cagrilintide is a long-acting amylin analogue. CagriSema combines these two satiety pathways in an effort to produce greater weight reduction than either component alone — part of the broader shift from single-pathway medications toward combination and multi-receptor approaches.
What REDEFINE 1 found (vs. placebo)
The Phase 3a, 68-week REDEFINE 1 trial randomized 3,417 adults with obesity, or overweight plus an obesity-related complication, without diabetes, to CagriSema, semaglutide alone, cagrilintide alone, or placebo, alongside lifestyle intervention. CagriSema produced mean weight reduction exceeding 20% at 68 weeks, versus roughly 3% with placebo — establishing that the amylin-plus-GLP-1 combination adds meaningfully to GLP-1 biology alone. The primary results were published in the New England Journal of Medicine in 2025.
Blood-pressure findings
A subsequent peer-reviewed secondary and post-hoc analysis, published in Hypertension, reported systolic blood pressure fell 10.9 mmHg with CagriSema versus 2.8 mmHg with placebo (diastolic: −5.4 vs. −1.7 mmHg), with a large share of participants on antihypertensive medication able to reduce or stop it. The value of obesity treatment extends beyond the scale to cardiovascular risk.
What REDEFINE 4 found (vs. Zepbound)
On February 23, 2026, Novo Nordisk reported topline results from REDEFINE 4, an open-label, randomized head-to-head trial in 809 adults with obesity comparing CagriSema with tirzepatide 15 mg over 84 weeks. CagriSema delivered 23.0% average weight loss — substantial by any historical standard — but the trial’s primary endpoint was to demonstrate non-inferiority to tirzepatide, and that endpoint was not met: tirzepatide averaged 25.5%. Novo has noted the open-label design as a possible influence and is studying higher CagriSema doses in ongoing trials.
How to read these results honestly
- 23% average weight loss is a strong result in absolute terms; missing a statistical non-inferiority margin does not make a medication ineffective.
- It does mean the best current randomized evidence favors tirzepatide, on average, for maximal weight reduction — replacing the cross-trial guesswork the field previously relied on.
- Open-label head-to-heads carry bias risks in both directions; the peer-reviewed publication will matter.
- Average results are not individual results: tolerability, comorbidities (such as hypertension), access, and cost still drive individual treatment selection.
- The pending FDA decision rests on the placebo-controlled REDEFINE 1 data, which pre-date REDEFINE 4.
BeLite Clinical Perspective
CagriSema remains important: it proves that amylin signaling adds to GLP-1 biology, and if approved it will expand the toolkit — particularly for patients in whom blood-pressure benefit matters. But a new medication does not need to be the market leader to be clinically useful, and no patient doing well on effective, approved therapy should switch or wait based on headlines. Treatment remains a clinical matching problem.
Frequently asked questions
Is CagriSema FDA-approved?
No. The application was filed in December 2025 and is under FDA review, with a decision expected late 2026. It is not available outside clinical trials.
Is CagriSema better than Zepbound?
The REDEFINE 4 head-to-head did not demonstrate non-inferiority to tirzepatide: average weight loss was 23.0% with CagriSema versus 25.5% with tirzepatide at 84 weeks. Individual response, tolerability, and other health effects still vary.
Is CagriSema simply a higher dose of semaglutide?
No. It combines semaglutide with cagrilintide, which acts through the separate amylin pathway.
What should patients do now?
Continue effective, approved treatment when clinically appropriate, and follow emerging evidence without assuming that every new therapy requires a switch.
References
- Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025;393:635–647. doi:10.1056/NEJMoa2502081. https://pubmed.ncbi.nlm.nih.gov/40544433/
- Verma S, et al. CagriSema reduces blood pressure in adults with overweight or obesity: REDEFINE 1. Hypertension. 2026;83. doi:10.1161/HYPERTENSIONAHA.125.26055. PMID 41328546. https://pubmed.ncbi.nlm.nih.gov/41328546/
- Novo Nordisk. CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity; the primary endpoint was not achieved. News release, February 23, 2026. ClinicalTrials.gov NCT06131437. Press Release
- Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema. News release, December 18, 2025. Press Release
About BeLite Medical Center
BeLite Medical Center in Northern, VA helps you reach your weight loss goals.
